Ambu AS (CHIX:AMBUBC) YoY EBITDA Growth: 24.32% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:AMBUBC Ambu AS CHIX:AMBUBC
80 GF Score
Price kr70.78
GF Value kr130.43
Valuation Significantly Undervalued
View Full Analysis

What is Ambu AS YoY EBITDA Growth?

Ambu AS CHIX:AMBUBC 80 YoY EBITDA Growth is 24.32% as of Jun. 2026. GuruFocus rates CHIX:AMBUBC with a GF Score™ of 80/100 and a GF Value™ of kr130.43 (Significantly Undervalued).

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Ambu AS's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 24.32%.

Ambu AS's EBITDA per Share for the three months ended in Jun. 2026 was kr1.24.

Ambu AS YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Ambu AS's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ambu AS YoY EBITDA Growth Chart

Ambu AS Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.45 -10.96 22.80 61.52 12.96

Ambu AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.19 -1.07 -20.64 -14.31 24.32
CHIX:AMBUBC
80GF Score
Ambu AS CHIX:AMBUBC
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ambu AS YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Ambu AS's YoY EBITDA Growth for the fiscal year that ended in Sep. 2025 is calculated as:

YoY EBITDA Growth (A: Sep. 2025 )
=(EBITDA per Share (A: Sep. 2025 )-EBITDA per Share (A: Sep. 2024 ))/ | EBITDA per Share (A: Sep. 2024 ) |
=(4.333-3.836)/ | 3.836 |
=12.96 %

Ambu AS's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(1.237-0.995)/ | 0.995 |
=24.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 24.32% mean?
Ambu AS (CHIX:AMBUBC) has a YoY EBITDA Growth of 24.32% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Ambu AS and its competitors.
Is Ambu AS's YoY EBITDA Growth too high?
Ambu AS's current YoY EBITDA Growth is 24.32%. Overall, Ambu AS has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ambu AS's YoY EBITDA Growth compare to ABT and SYK?
Ambu AS's YoY EBITDA Growth of 24.32% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Ambu AS and its competitors. Ambu AS's current YoY EBITDA Growth is 24.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambu AS stock overvalued right now?
Based on GuruFocus' analysis, Ambu AS (CHIX:AMBUBC) is currently considered Significantly Undervalued. The stock's GF Value™ is kr130.43, compared to a current price of kr70.78 — trading 45.7% below its estimated fair value. The current YoY EBITDA Growth is 24.32%. Ambu AS's overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Ambu AS (CHIX:AMBUBC), the current YoY EBITDA Growth is 24.32% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ambu AS (CHIX:AMBUBC) Overvalued in 2026?

Based on GuruFocus' analysis, Ambu AS stock appears to be undervalued. The current stock price of kr70.78 is trading 45.7% below its estimated GF Value™ of kr130.43. GuruFocus considers Ambu AS to be Significantly Undervalued.

Key valuation signals for CHIX:AMBUBC:

  • YoY EBITDA Growth: 24.32%
  • GF Value™: kr130.43 vs. price of kr70.78 (45.7% below fair value)
  • GF Score™: 80/100

No single metric tells the full story. See the CHIX:AMBUBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ambu AS Business Description

Address Baltorpbakken 13, Ballerup, DNK, DK-2750
Ambu AS provides medical technology solutions. The company's business consists of research and development of new solutions, which are then manufactured, marketed, and sold. It operates in two verticals: Endoscopy Solutions and Anesthesia & Patient Monitoring, with the majority of revenue being generated from the Endoscopy Solutions business. Geographical segments include North America, Europe, and the Rest of the World.
80GF Score

Get the complete analysis for CHIX:AMBUBC

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr70.78
Price
kr130.43
GF Value